SG11202006490YA - 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases - Google Patents

2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Info

Publication number
SG11202006490YA
SG11202006490YA SG11202006490YA SG11202006490YA SG11202006490YA SG 11202006490Y A SG11202006490Y A SG 11202006490YA SG 11202006490Y A SG11202006490Y A SG 11202006490YA SG 11202006490Y A SG11202006490Y A SG 11202006490YA SG 11202006490Y A SG11202006490Y A SG 11202006490YA
Authority
SG
Singapore
Prior art keywords
pyrazolo
pyrimidin
tetrahydro
derivatives
inflammatory diseases
Prior art date
Application number
SG11202006490YA
Other languages
English (en)
Inventor
Sylvie Froidevaux
Francis Hubler
Mark Murphy
Dorte Renneberg
Simon Stamm
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of SG11202006490YA publication Critical patent/SG11202006490YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
SG11202006490YA 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases SG11202006490YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018050598 2018-01-10
PCT/EP2019/050372 WO2019137927A1 (en) 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Publications (1)

Publication Number Publication Date
SG11202006490YA true SG11202006490YA (en) 2020-08-28

Family

ID=65012016

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006490YA SG11202006490YA (en) 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Country Status (29)

Country Link
US (2) US11608341B2 (ja)
EP (1) EP3737684B1 (ja)
JP (1) JP7014914B2 (ja)
KR (1) KR102574564B1 (ja)
CN (1) CN111566109B (ja)
AR (1) AR114564A1 (ja)
AU (1) AU2019207666B2 (ja)
BR (1) BR112020013788A2 (ja)
CA (1) CA3086310C (ja)
CL (1) CL2020001817A1 (ja)
DK (1) DK3737684T3 (ja)
EA (1) EA202091641A1 (ja)
ES (1) ES2933820T3 (ja)
HR (1) HRP20221449T1 (ja)
HU (1) HUE060515T2 (ja)
IL (1) IL275868B2 (ja)
LT (1) LT3737684T (ja)
MA (1) MA51558B1 (ja)
MX (1) MX2020007443A (ja)
PH (1) PH12020500583A1 (ja)
PL (1) PL3737684T3 (ja)
PT (1) PT3737684T (ja)
RS (1) RS63806B1 (ja)
SG (1) SG11202006490YA (ja)
SI (1) SI3737684T1 (ja)
TW (2) TWI839788B (ja)
UA (1) UA124694C2 (ja)
WO (1) WO2019137927A1 (ja)
ZA (1) ZA202004910B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060515T2 (hu) * 2018-01-10 2023-03-28 Idorsia Pharmaceuticals Ltd 2,4,6,7-Tetrahidro-pirazolo[4,3-d]pirimidin-5-on származékok és rokon vegyületek mint C5A receptor modulátorok vasculitis és gyulladásos betegségek kezelésére
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
US11739070B2 (en) 2018-01-19 2023-08-29 Idorsia Pharmaceuticals Ltd. C5A receptor modulators
RS65511B1 (sr) * 2019-07-09 2024-06-28 Idorsia Pharmaceuticals Ltd Farmaceutska kompozicija koja sadrži jedinjenje tetrahidropirazolopirimidinon
US11193891B2 (en) * 2019-12-20 2021-12-07 Robert Bosch Gmbh Receptors and spacers for a fluorescence-based lead ion chemosensor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
HUE033644T2 (en) 2010-06-24 2017-12-28 Chemocentryx Inc C5AR antagonists
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
TWI657090B (zh) * 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
PE20160432A1 (es) 2013-09-04 2016-05-11 Bristol Myers Squibb Co Compuestos utiles como inmunomoduladores
AU2014316682B2 (en) 2013-09-06 2018-11-22 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CN110305133A (zh) * 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
US9682940B2 (en) 2015-08-25 2017-06-20 Janssen Pharmaceutica Nv Indazole derivatives useful as CB-1 inverse agonists
HUE060515T2 (hu) * 2018-01-10 2023-03-28 Idorsia Pharmaceuticals Ltd 2,4,6,7-Tetrahidro-pirazolo[4,3-d]pirimidin-5-on származékok és rokon vegyületek mint C5A receptor modulátorok vasculitis és gyulladásos betegségek kezelésére
US11739070B2 (en) 2018-01-19 2023-08-29 Idorsia Pharmaceuticals Ltd. C5A receptor modulators
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
RS65511B1 (sr) 2019-07-09 2024-06-28 Idorsia Pharmaceuticals Ltd Farmaceutska kompozicija koja sadrži jedinjenje tetrahidropirazolopirimidinon

Also Published As

Publication number Publication date
MA51558B1 (fr) 2022-12-30
HUE060515T2 (hu) 2023-03-28
SI3737684T1 (sl) 2023-01-31
AU2019207666A1 (en) 2020-08-27
CA3086310C (en) 2023-09-19
JP7014914B2 (ja) 2022-02-01
TWI839788B (zh) 2024-04-21
TW201930307A (zh) 2019-08-01
US11608341B2 (en) 2023-03-21
KR20200106061A (ko) 2020-09-10
CN111566109B (zh) 2023-07-11
US20200369672A1 (en) 2020-11-26
ZA202004910B (en) 2024-02-28
PT3737684T (pt) 2022-12-20
CL2020001817A1 (es) 2020-12-04
HRP20221449T1 (hr) 2023-01-20
ES2933820T3 (es) 2023-02-14
TW202244047A (zh) 2022-11-16
IL275868B2 (en) 2023-06-01
JP2021510373A (ja) 2021-04-22
US20230192708A1 (en) 2023-06-22
LT3737684T (lt) 2022-12-27
PH12020500583A1 (en) 2021-06-14
EP3737684B1 (en) 2022-11-16
AU2019207666B2 (en) 2023-12-21
RS63806B1 (sr) 2023-01-31
MX2020007443A (es) 2020-09-14
TWI774905B (zh) 2022-08-21
DK3737684T3 (da) 2022-12-12
BR112020013788A2 (pt) 2020-12-01
EA202091641A1 (ru) 2020-11-17
EP3737684A1 (en) 2020-11-18
AR114564A1 (es) 2020-09-23
IL275868A (en) 2020-08-31
MA51558A (fr) 2021-04-14
CN111566109A (zh) 2020-08-21
WO2019137927A1 (en) 2019-07-18
PL3737684T3 (pl) 2023-02-27
UA124694C2 (uk) 2021-10-27
KR102574564B1 (ko) 2023-09-04
CA3086310A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
ZA202004910B (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物
IL270909A (en) Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
EP3107914B8 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
IL283149A (en) Inhibitors of HPK1 and their use in the treatment of cancer
DK3953357T3 (en) Pyrrolotriazine derivatives for treating KIT- and PDGFRA-mediated diseases
PL3697784T3 (pl) Związki imidazo[4,5-b]pirydyny i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych
PL3500571T3 (pl) Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
DK3177627T3 (da) Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
PT3277687T (pt) Derivados de 7-(morfolin-4-il)pirazole[1,5-a]pirimidina que são úteis para o tratamento de doenças imunitárias ou inflamatórias ou cancro
IL253427A0 (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose
HK1257427A1 (zh) 用於製備2-吡唑並[1,5-a]吡嗪-2-基吡啶並[1,2-a]嘧啶-4-酮的方法